(Bloomberg) -- Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the company still faces after its $63 billion acquisition of ...

Bayer has issued a robust defence of Essure after ... cherry-picking information to fit a predetermined conclusion, ignoring the full body of scientific evidence that supports the FDA’s ...